Abstracts Archive - Page 1415 of 2425 - ACR Meeting Abstracts

Abstract Number: 112 • 2017 Pediatric Rheumatology Symposium
Use of Rituximab and Risk of Re-hospitalization for Children with Neuromyelitis Optica Spectrum Disorder
Sabrina Gmuca¹, Amy T. Waldman², Pamela F. Weiss³ and Jeffrey S. Gerber², ¹Pediatric Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, ²The Children's Hospital of Philadelphia, Philadelphia, PA, ³Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: First-line use of rituximab for neuromyelitis optica spectrum disorder (NMOSD) is common but the benefits of early immunosuppression remain unclear. We aimed to determine…
Abstract Number: 132 • 2017 Pediatric Rheumatology Symposium
Influence of Juvenile Idiopathic Arthritis Fibroblast-like Synoviocytes and Mature Chondrocytes on Each Other in Culture: A Pilot Study
Amanda R. Schlefman¹, Megan M. Simonds², Kathleen E. Sullivan³, Carlos D. Rosé¹ and AnneMarie C. Brescia¹, ¹Pediatric Rheumatology, Nemours/Thomas Jefferson University, Wilmington, DE, ²Nemours Biomedical Research, Wilmington, DE, ³Pediatrics, University of Pennsylvania, Philadelphia, PA
Background/Purpose: A chondrocyte-like phenotype has previously been described in pediatric fibroblast-like synoviocytes (FLS), which may contribute to bony overgrowth in juvenile idiopathic arthritis (JIA). The…
Abstract Number: 23 • 2017 Pediatric Rheumatology Symposium
Impact of an Institutional Specialty Pharmacy on Adherence to Biologic Therapies
Kelly Wise¹, Dustin Lewis², Bethanne Thomas², Karla Jones³, Stephanie Lemle², Darby MacDonald², Fatima Barbar-Smiley², Vidya Sivaraman² and Cagri Yildirim-Toruner³, ¹Pharmacy/Rheumatology, Nationwide Children's Hospital, Columbus, OH, ²Nationwide Children's Hospital, Columbus, OH, ³Rheumatology, Nationwide Children's Hospital, Columbus, OH
Background/Purpose: Biologic therapies have become a standard of care for many pediatric rheumatic diseases such as juvenile idiopathic arthritis (JIA) and periodic fever syndromes. Biologics,…
Abstract Number: 119 • 2017 Pediatric Rheumatology Symposium
Establishment of registry for pediatric rheumatic diseases in Japan: Pediatric Rheumatology International Collaboration Unit Registry (PRICURE) survey
Tomoyuki Imagawa¹, Ken-ichi Yamaguchi², Yuzaburo Inoue³, Hidehiko Narasaki⁴, Yasuhito Nerome⁵ and Yasuhiko Itoh⁴, ¹Department of Infectious diseases and Immunology, Kanagawa Children’s Medical Center, Yokohama, Japan, ²Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ³Department of Pediatrics, Eastern Chiba Medical Center, Togane, Japan, ⁴Department of Pediatrics, Nippon Medical School, Tokyo, Japan, ⁵Department of Community-Based Medicine Education Center for Doctors in Remote Islands and Rural Areas, Kagoshima University, Kagoshima, Japan
Background/Purpose: To identify the number and characteristics of Japanese pediatric diseases, Pediatric Rheumatology International Collaboration Unit Registry (PRICURE) survey was established by Pediatric Rheumatology Association…
Abstract Number: 45 • 2017 Pediatric Rheumatology Symposium
Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn’s Disease
Gerd Horneff¹, Marieke M. B. Seyger², Dilek Arikan³, Jasmina Kalabic⁴, Jaclyn K. Anderson³, Andreas Lazar⁵, David A. Williams³, Chen Wang³, Rita Tarzynski-Potempa³ and Jeffrey S. Hyams⁶, ¹Asklepios Clinic, Sankt Augustin, Germany, ²Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁵AbbVie Deutschland GmbH & Co. KG, North ChicagoLudwigshafen, IL, Germany, ⁶Connecticut Children’s Medical Center, Hartford, CT
Background/Purpose: Adalimumab (ADA) is a tumor necrosis factor (TNF) inhibitor used for treatment of chronic immune diseases. The safety of ADA treatment in pediatric patients…
Abstract Number: 148 • 2017 Pediatric Rheumatology Symposium
Oral Microbial Profile in Juvenile Idiopathic Arthritis
Sriharsha Grevich^1,2, Peggy Lee³, Jeffrey McLean³, Brian Leroux³, Sarah Ringold^1,2, Kyle Hager⁴, Mitchell Brittnacher⁴, Hillary Hayden⁴, Samuel Miller⁴ and Anne Stevens^1,2,5, ¹University of Washington, Department of Pediatrics, Seattle, WA, ²Seattle Children's Hospital, Seattle, WA, ³University of Washington, School of Dentistry, Seattle, WA, ⁴University of Washington, Department of Microbiology, Seattle, WA, ⁵Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA
Background/Purpose: Microbial communities in the mouth have been associated with the chronic inflammation of periodontitis and rheumatoid arthritis (RA), and there is higher prevalence of…
Abstract Number: 13 • 2017 Pediatric Rheumatology Symposium
Prevalence of Celiac Antibodies and IgA deficiency in Juvenile Idiopathic Arthritis
Angela Taneja¹, Sampath Prahalad², Aimee O. Hersh³, Lori Ponder⁴, Lai Hin Kimi Chan⁵, Kelly A. Rouster-Stevens⁶, Anne E Tebo⁷, Subramanian Kugathasan⁸ and John F. Bohnsack⁹, ¹Pediatric Rheumatology, Emory University School of Medicine, Atlanta, GA, ²Pediatrics, Emory Children's Center, Atlanta, GA, ³Pediatrics/Rheumatology, University of Utah, Salt Lake City, UT, ⁴Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, ⁵Pediatrics, Emory University School of Medicine, Atlanta, GA, ⁶Pediatric Rheumatology, Emory Children's Center, Atlanta, GA, ⁷University of Utah, Salt Lake City, UT, ⁸Gastroenterology, Emory University School of Medicine, Atlanta, GA, ⁹Division of Allergy, Immunology and Pediatric Rheumatology, University of Utah, Salt Lake City, UT
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common chronic arthritis of childhood. The prevalence of autoimmunity is higher in JIA cases and relatives.…
Abstract Number: 87 • 2017 Pediatric Rheumatology Symposium
Assessment of Endothelial Dysfunction and Atherogenic Risk Factors in Children with Juvenile Dermatomyositis
Dawn Wahezi¹, Emily Liebling², Jillian Parekh², Marija Dionizovik-Dimanovski¹, Jaeun Choi³ and Qi Gao³, ¹Pediatric Rheumatology, Children's Hospital at Montefiore, Bronx, NY, ²Pediatrics, Children's Hospital at Montefiore, Bronx, NY, ³Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Endothelial pulse amplitude testing (Endo-PAT) measures changes in vascular tone by post-occlusive hyperemic response. A reduced hyperemic response suggests endothelial dysfunction and serves as…
Abstract Number: 100 • 2017 Pediatric Rheumatology Symposium
Improvement of Salivary Gland Ultrasound Findings in Juvenile Sjögren’s Syndrome after Systemic Corticosteroid Treatment
Akaluck Thatayatikom¹, Renee F Modica², Daniel S. Hammenfors³, Natalie Jane Shiff¹ and Melissa E Elder², ¹Pediatrics, University of Florida, Gainesville, FL, ²Department of Pediatrics, University of Florida, Gainesville, FL, ³Department of Rheumatology, Haukeland University Hospital, Bergen, Norway
Background/Purpose: Juvenile Sjögren’sSyndrome (jSS) is a rare systemic autoimmune disease affecting predominantly salivary glands (SG) in children who do not meet criteria for SLE or MCTD. Currently, no specific criteria for…
Abstract Number: 5 • 2017 Pediatric Rheumatology Symposium
Effects of Puberty on Systemic Lupus Erythematosus: Results of a multi-center prospective longitudinal observational study in children entering puberty with SLE
Kathleen O'Neil¹, Hermine Brunner², Andrew Zeft³, Anne Stevens⁴, Suzanne Li⁵, Tracey Wright⁶, Emily von Scheven⁷, B. Anne Eberhard⁸, C. Egla Rabinovich⁹ and Deborah M. Levy¹⁰, ¹Pediatrics, Indiana University, Indianapolis, IN, ²Rheumatology, PRCSG, Cincinnati, OH, ³Pediatrics Rheumatology, Cleveland Clinic, Cleveland, OH, ⁴University of Washington, Department of Pediatrics, Seattle, WA, ⁵Pediatrics, Joseph M Sanzari Children’s Hospital, Hackensack Meridian Health, Hackensack, NJ, ⁶Pediatrics/Rheumatology, University of TX Southwestern, Dallas, TX, ⁷Division of Rheumatology, Department of Pediatrics, University of California San Francisco, San Francisco, CA, ⁸Cohen Children's Medical Center of New York, New Hyde Park, NY, ⁹Pediatric Rheumatology, Duke University Medical Center, Durham, NC, ¹⁰Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Lupus often presents during puberty, and when it affects pre-pubertal children, disease activity is thought to increase at puberty. Sex hormones play some role…
Abstract Number: 155 • 2017 Pediatric Rheumatology Symposium
A Single Center Review of Health Related Quality of Life in Children with Systemic Lupus Erythematosus Using the Pediatric Quality of Life Inventory Version 4.0 Generic Core Scale
JaLeen Rogers¹, Anna Carmela P. Sagcal-Gironella², Patricia Rosillo³, Andrea A. Ramirez⁴, Rosa Banuelos⁵ and Marietta M. de Guzman⁶, ¹Outcomes and Impact Services, Texas Children's Hospital, Houston, TX, ²Rheumatology, Texas Children's Hospital, Houston, TX, ³Allergy, Immunology and Rheumatology, Baylor College of Medicine/Texas Children's Hospital, Houston, TX, ⁴Pediatric Rheumatology, Texas Children's Hospital, Houston, TX, ⁵Texas Children's Hospital, Houston, TX, ⁶Department of Pediatrics, Division of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Systemic lupus erythematosus (SLE) can cause adverse effects in various aspects of daily functioning for pediatric patients. Measuring Health-related Quality of Life (HRQOL) provides…
Abstract Number: 61 • 2017 Pediatric Rheumatology Symposium
Which Juvenile Idiopathic Arthritis patient is more likely to have Temporomandibular Joint involvement?
shelly abramowicz¹, joshua levy², Curtis Travers³, Sampath Prahalad⁴ and Sheila Angeles-Han⁵, ¹Surgery, Emory University/Children's Healthcare of Atlanta, atlanta, GA, ²Surgery, Emory University, atlanta, GA, ³Pediatrics, Emory University School of Medicine, Atlanta, GA, ⁴Pediatrics, Emory Children's Center, Atlanta, GA, ⁵Department of Pediatrics, Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) affects approximately 300,000 children in the United States. Temporomandibular joint (TMJ) involvement in children with JIA can lead to decreased…
Abstract Number: 62 • 2017 Pediatric Rheumatology Symposium
Novel Approach to Quantifying Joint Pathology Via Musculoskeletal Ultrasound in Newly Diagnosed Juvenile Idiopathic Arthritis
Leandra Woolnough¹, David Wilkes², Yassine Kanaan², Tracey Wright³ and Heather Benham⁴, ¹UT Southwestern Medical Center, DALLAS, TX, ²Texas Scottish Rite Hospital for Children, Dallas, TX, ³Pediatrics/Rheumatology, UT Southwestern Medical Center, Dallas, TX, ⁴Pediatric Rheumatology, Texas Scottish Rite Hospital for Children, Dallas, TX
Background/Purpose: The pathology of inflammation in Juvenile Idiopathic Arthritis (JIA), including thickening and vascularization of the synovial membrane, joint effusion and bony erosions, can be…
Abstract Number: 26 • 2017 Pediatric Rheumatology Symposium
Gray Matter Volume Loss in Youth with SLE
Andrea Knight¹, Michelle Vickery², Arastoo Vossough³, Guray Erus⁴, Jimit Doshi⁵ and Susan Furth⁶, ¹Center for Pediatric Clinical Effectiveness & PolicyLab, Philadelphia, PA, ²PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, ³Radiology, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Section on Biomedical Image Analysis, University of Pennsylvania, Philadelphia, PA, ⁵Section of Biomedical Image Analysis, University of Pennsylvania, Philadelphia, PA, ⁶Division of Nephrology, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Neuropsychiatric SLE in children and adolescents presents diagnostic challenge due to limitations of conventional magnetic resonance imaging (MRI) to detect clinically relevant brain changes.…
Abstract Number: 60 • 2017 Pediatric Rheumatology Symposium
Paediatric Arthritis Rehabilitation Exercise Study
Claire LeBlanc^1,2, Sophie Laniel³, Michele Geoffrion⁴, Alexandra Sirois⁵, Sofia Nene⁶, Sophie Cloutier⁷, Yun Gao⁸, Karine Toupin-April⁹, Sarah Campillo¹⁰, Gaëlle Chédeville¹¹ and Rosie Scuccimarri¹², ¹Pediatrics, Montreal Children's Hospital, Montreal, QC, Canada, ²Montreal Children's Hospital, McGill University, Montreal, QC, Canada, ³rehabilitaion medicine, co-PI, Montreal, QC, Canada, ⁴rehabilitation, co-PI, Montreal, QC, Canada, ⁵Kinesiology, Student, Montreal, QC, Canada, ⁶medicine, research student, Montreal, QC, Canada, ⁷pediatrics, research student, Montreal, QC, Canada, ⁸research student, Montreal, QC, Canada, ⁹Children’s Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada, ¹⁰Montreal Children's Hospital, Montreal, QC, Canada, ¹¹Rheumatology, McGill University, Montreal, QC, Canada, ¹²Division of Pediatric Rheumatology, Montreal Children's Hospital/McGill University Health Centre, Montreal, QC, Canada
JIA patients often require regular exercises to increase joint range of motion (ROM). Adherence is challenging; instruction by a physiotherapist (PT) / occupational therapist (OT)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].